Treatment Persistence in Atrial Fibrillation: The Next Major Hurdle

Elaine M. Hylek

doi:10.1055/s-0038-1676101

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2018; 118(12): 2018-2019
DOI: 10.1055/s-0038-1676101

Invited Editorial Focus

Georg Thieme Verlag KG Stuttgart · New York

Treatment Persistence in Atrial Fibrillation: The Next Major Hurdle

Autoren

Elaine M. Hylek

¹Department of Internal Medicine, Boston University, Boston, Massachusetts, United States

Abstract

Volltext

Referenzen

References
1 Geng YP, Lan DH, Liu N. , et al. Patient-reported treatment satisfaction with dabigatran versus warfarin in patients with non-valvular atrial fibrillation in China. Thromb Haemost 2018; 118 (10) 1815-1822
2 Jackevicius CA, Tsadok MA, Essebag V. , et al. Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation. Heart 2017; 103 (17) 1331-1338
3 Martinez C, Katholing A, Wallenhorst C, Freedman SB. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost 2016; 115 (01) 31-39
4 Beyer-Westendorf J, Ebertz F, Förster K. , et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 2015; 113 (06) 1247-1257
5 Vedovati MC, Verdecchia P, Giustozzi M. , et al. Permanent discontinuation of non vitamin K oral anticoagulants in real life patients with non-valvular atrial fibrillation. Int J Cardiol 2017; 236: 363-369
6 Jackson II LR, Kim S, Shrader P. , et al. Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. J Thromb Thrombolysis 2018; 46 (04) 435-439
7 Yao X, Abraham NS, Alexander GC. , et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc 2016; 5 (02) e003074
8 Patel MR, Mahaffey KW, Garg J. , et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
9 Granger CB, Alexander JH, McMurray JJ. , et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
10 Lip G, Freedman B, De Caterina R, Potpara TS. Stroke prevention in atrial fibrillation: past, present and future. Comparing the guidelines and practical decision-making. Thromb Haemost 2017; 117 (07) 1230-1239
11 Weernink MGM, Vaanholt MCW, Groothuis-Oudshoorn CGM, von Birgelen C, IJzerman MJ, van Til JA. Patients' priorities for oral anticoagulation therapy in non-valvular atrial fibrillation: a multi-criteria decision analysis. Am J Cardiovasc Drugs 2018 10.1007/s40256-018-0293-0
12 Loewen PS, Ji AT, Kapanen A, McClean A. Patient values and preferences for antithrombotic therapy in atrial fibrillation. A narrative systematic review. Thromb Haemost 2017; 117 (06) 1007-1022
13 Aronis KN, Thigpen JL, Tripodis Y. , et al. Paroxysmal atrial fibrillation and the hazards of under-treatment. Int J Cardiol 2016; 202: 214-220
14 Camm AJ, Accetta G, Ambrosio G. , et al; GARFIELD-AF Investigators. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart 2017; 103 (04) 307-314
15 Vinereanu D, Lopes RD, Bahit MC. , et al; IMPACT-AF investigators. A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial. Lancet 2017; 390 (10104): 1737-1746
16 Hess PL, Mirro MJ, Diener HC. , et al; Atrial Fibrillation Think-Tank Participants. Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. Am Heart J 2014; 168 (03) 239-247
17 Steffel J, Verhamme P, Potpara TS. , et al; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39 (16) 1330-1393
18 Raparelli V, Proietti M, Cangemi R, Lip GY, Lane DA, Basili S. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. Thromb Haemost 2017; 117 (02) 209-218